A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

NCT ID: NCT00538785

Last Updated: 2012-02-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

1236 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective was to describe the safety and tolerability of motavizumab when given monthly as prophylaxis against serious RSV infection among children with hemodynamically significant congenital heart disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Motavizumab

Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.

Group Type EXPERIMENTAL

Motavizumab

Intervention Type BIOLOGICAL

15 mg/kg IM administered at monthly intervals

Pailvizumab

Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.

Group Type ACTIVE_COMPARATOR

Palivizumab

Intervention Type BIOLOGICAL

15 mg/kg IM administered at monthly intervals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Motavizumab

15 mg/kg IM administered at monthly intervals

Intervention Type BIOLOGICAL

Palivizumab

15 mg/kg IM administered at monthly intervals

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medi-524 Synagis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 24 months of age or younger at randomization (child must have been randomized on or before their 24-month birthday)
* Documented, hemodynamically significant CHD
* Unoperated or partially corrected CHD
* Written informed consent obtained from the patient's parent(s)/legal guardian(s) Note: The following children were not eligible: children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus, children with aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone. Children with acyanotic cardiac lesions must have pulmonary hypertension \[≥ 40 mmHg measured pressure in the pulmonary artery (PA)\] or the need for daily medication to manage CHD.

Exclusion Criteria

* Unstable cardiac or respiratory status, including cardiac defects so severe that survival was not expected or for which cardiac transplantation was planned or anticipated
* Hospitalization, unless discharge was anticipated within 21 days
* Anticipated cardiac surgery within two weeks of randomization
* Requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support
* Associated non-cardiac anomalies or end organ dysfunction resulting in anticipated survival of less than six months or unstable abnormalities of end organ function
* Acute respiratory illness, or other acute infection or illness Note: children with any respiratory symptoms must have had a negative RSV test prior to randomization
* Chronic seizure or evolving or unstable neurologic disorder
* Known immunodeficiency
* Mother with HIV infection (unless the child had been proven to be not infected)
* Known allergy to Ig products
* Receipt of any polyclonal antibody (for example, Hepatitis B IG, IVIG, VZIG) within 3 months prior to randomization
* Receipt of palivizumab (Synagis®) within 3 months prior to randomization
* Use of investigational agents within the past three months (other than investigational agents commonly used during cardiac surgery or the immediate post-operative period, e.g., nitric oxide)
* Current participation in other investigational protocols of drugs or biological agents
* Previous participation in MI-CP124 (Season 1)
Maximum Eligible Age

24 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedImmune LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MedImmune, LLC

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pamela Griffin, 301-398-0000

Role: STUDY_DIRECTOR

MedImmune LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Pediatric Clinic

Little Rock, Arkansas, United States

Site Status

Miller Children's Hospital

Long Beach, California, United States

Site Status

Childrens Hospital Los Angeles

Los Angeles, California, United States

Site Status

Children's Hospital and Research Center at Oakland

Oakland, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

Children's Hospital And Health Center

San Diego, California, United States

Site Status

Yale New Haven Children's Hospital

New Haven, Connecticut, United States

Site Status

Children's National Medical Center

Washington D.C., District of Columbia, United States

Site Status

Nemours Children's Clinic Biomedical Research Department

Orlando, Florida, United States

Site Status

James Whitcomb Riley Hospital for Children

Indianapolis, Indiana, United States

Site Status

Memorial Hospital of South Bend

South Bend, Indiana, United States

Site Status

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

Tufts - New England Medical Center

Boston, Massachusetts, United States

Site Status

Children's Hospital Boston

Boston, Massachusetts, United States

Site Status

Children's Hospital of Michigan

Detroit, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Children's Mercy Hospital

Kansas City, Missouri, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

Suny At Stony Brook University Medical Center

Stony Brook, New York, United States

Site Status

Univ. of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Akron Children's Hospital

Akron, Ohio, United States

Site Status

Children's Hospital of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Children's Cardiology Associates PLLC

Austin, Texas, United States

Site Status

Texas Children's Hospital

Houston, Texas, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Universitätsklinik für Kinder- und Jugendheilkunde

Innsbruck, , Austria

Site Status

Allgemeines Krankenhaus Linz

Linz, , Austria

Site Status

Universitätsklinik für Kinder- und Jugendheilkunde

Wein, , Austria

Site Status

Ziekenhuisnetwerk Antwerpen - Koningin Paola Kinderziekenhuis

Antwerp, , Belgium

Site Status

UZ Brussel

Brussells, , Belgium

Site Status

Hôpital Universitaire des Enfants Reine

Brussels, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

UZ Antwerpen

Edegem, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

CHR de la Citadelle

Liège, , Belgium

Site Status

University Multifunctional Hospital for Active Treatment

Pleven, , Bulgaria

Site Status

University Mulitiprofile Hospital for Active Treatment "St.Georgi"

Plovdiv, , Bulgaria

Site Status

Multifunctional Hospital for Active Treatment - Pleven

Plovdiv, , Bulgaria

Site Status

Regional Dispensary for Pulmonary Diseases with Inpatient sector-Rousse

Rousse, , Bulgaria

Site Status

Specialized Hospital for Active Treatment of Cardio-vascular Diseases

Sofia, , Bulgaria

Site Status

Specialized Hospital for Active Treatment of Pediatric Diseases

Sofia, , Bulgaria

Site Status

University Multifunctional Hospital for Active Treatment

Stara Zagora, , Bulgaria

Site Status

Multifunctional Hospital for Active Treatment - Pleven

Varna, , Bulgaria

Site Status

Children's and Women's Hospital of BC, Room #1R11

Vancouver, British Columbia, Canada

Site Status

IWK Health Center

Halifax, Nova Scotia, Canada

Site Status

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status

University of Alberta

Edmonton, , Canada

Site Status

Montreal Children's Hospital

Montreal, , Canada

Site Status

Saint Justine Hospital

Montreal, , Canada

Site Status

Children's Hospital Of Eastern Ontario

Ottawa, , Canada

Site Status

Saskatchewan Drug Research Institute

Saskatoon SK, , Canada

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Nemocnice Most, prispevkova organizace

Most, , Czechia

Site Status

Fakultni nemocnice Plzen

Plzen - Lochotin, , Czechia

Site Status

Vseobecna fakultni nemocnice v Praze

Prague, , Czechia

Site Status

Ustav pro peci o matku a dite

Prague, , Czechia

Site Status

Fakultni nemocnice v Motole

Prague, , Czechia

Site Status

Fakultni nemocnice Na Bulovce

Prague, , Czechia

Site Status

Skejby Sygehus

Århus N, , Denmark

Site Status

Groupe Hospitalier Pelligrin

Bordeaux, , France

Site Status

CHRU Dijon-Complex du Bocage

Dijon, , France

Site Status

Centre chirurgical Marie Lannelongue

Le Plessis-Robinson, , France

Site Status

Hospital de la Conception

Marseille, , France

Site Status

Hospital Robert Debre

Paris, , France

Site Status

American Memorial Hospital

Reims, , France

Site Status

Hospital de Hautepierre

Strasbourg, , France

Site Status

Hospitaux de Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Herz- und Diabeteszentrum NRW

Bad Oeynhausen, , Germany

Site Status

Friedrich-Alexander-Universiät Erlangen Nürnberg

Freiburg im Breisgau, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Universitätsklinikum Schleswig Holstein

Kiel, , Germany

Site Status

Johannes Gutenberg-Universität

Mainz, , Germany

Site Status

LMU Klinikum der Universität

München, , Germany

Site Status

Klinikum Oldenburg

Oldenburg, , Germany

Site Status

Universitätsklinik Rostock

Rostock, , Germany

Site Status

Universitätsklinik Rostock

Rostock, , Germany

Site Status

Universitätsklinikum Tübingen

Tübingen, , Germany

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Gyermeksziv Kozpont

Budapest, , Hungary

Site Status

Debreceni Egyetem OEC

Debrecen, , Hungary

Site Status

Petz Aladar Megyei Korhaz

Győr, , Hungary

Site Status

Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház

Miskolc, , Hungary

Site Status

Josa Andras Korhaz

Nyíregyháza, , Hungary

Site Status

Pecsi Tudomanyegyetem

Pécs, , Hungary

Site Status

Szegedi Tudomanyegyetem AOK, Gyermekgyogyaszati Klinika

Szeged, , Hungary

Site Status

Veszprém Megyei Önkormányzat - Csolnoky Ferenc Kórház

Veszprém, , Hungary

Site Status

Soroka University Medical Center

Beersheba, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Edith Wolfson Medical Center

Holon, , Israel

Site Status

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status

Hadassah University Hospital Ein Kerem

Jerusalem, , Israel

Site Status

Schneider Children's Medical Center of Israel

Petah Tikva, , Israel

Site Status

The Chaim Sheba Medical Center

Ramat Gan, , Israel

Site Status

Tel-Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

The Chaim Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

St George University Hospital

Achrafieh- Beirut, , Lebanon

Site Status

American University of Beirut Medical Center

Beirut, , Lebanon

Site Status

Hotel Dieu De France

Beirut, , Lebanon

Site Status

Samodzielny Publiczny Szpital Akademii Medycznej

Bialystok, , Poland

Site Status

Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Wojewodzki Szpital im. dr Jana Biziela w Bydgoszczy

Bydgoszcz, , Poland

Site Status

Wojewodzki Szpital Dzieciecy W Bydgoszczy

Bydgoszcz, , Poland

Site Status

Instytut Centrum Zdrowia Matki Polki

Lodz, , Poland

Site Status

Dzieciecy Szpital Kliniczny im. Prof. Antoniego Gebal Poliklinika

Lubin, , Poland

Site Status

Ginekologiczno-Poloznicy Szpital Kliniczny Uniwersytetu Medycznego w Poznaniu

Poznan, , Poland

Site Status

Szpital Kliniczny Uniwersytetu Medycznego im. Karola Jonschera

Poznan, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny nr 1 im. Tadeusza Sokolowskiego Pomorskiej AM w Szczecinie

Szczecin, , Poland

Site Status

Instytut "Pomnik - Centrum Zdrowia Dziecka"

Warsaw, , Poland

Site Status

Kazan State Medical University

Kazan', , Russia

Site Status

Kuban State Medical Academy

Krasnodar, , Russia

Site Status

Meshalkin Research Institue of Blood circulation

Novosibirsk, , Russia

Site Status

City Outpatient Clinic #113

Saint Petersburg, , Russia

Site Status

Saint Petersburg State Pediatric Medical Academy

Saint Petersburg, , Russia

Site Status

St. Petersburg City Children's Hospital #1

Saint Petersburg, , Russia

Site Status

Research Cardiology Institute of Tomsk Scientific Center

Tomsk, , Russia

Site Status

St. Petersburg Pediatric city hospital

Tyumen, , Russia

Site Status

Hospital Juan Canalejo

A Coruña, , Spain

Site Status

Hospital de Cruces

Barakaldo, , Spain

Site Status

Hospital Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Reina Sofia

Córdoba, , Spain

Site Status

Hospital Donostia

Donostia / San Sebastian, , Spain

Site Status

Hospital Universitario Virgen de la Arrixaca

El Palmar, , Spain

Site Status

Hospital Sant Joan de Deu

Esplugas de Llobregat, , Spain

Site Status

Hospital Josep Trueta

Girona, , Spain

Site Status

Hospital Universitario Virgen de Las Nieves

Granada, , Spain

Site Status

Hospital Materno Infantil de Jaen

Jaén, , Spain

Site Status

Hospital de Jerez

Jerez de la Frontera, , Spain

Site Status

Hospital Gregorio Marañon

Madrid, , Spain

Site Status

Hospital La Paz

Madrid, , Spain

Site Status

Hospital 12 de Octubre

Madrid, , Spain

Site Status

Hospital Materno Infantil

Málaga, , Spain

Site Status

Hospital Infantil Universitario Virgen del Rocío

Seville, , Spain

Site Status

Hospital Xeral de Vigo

Vigo, , Spain

Site Status

Hospital Universitario Miguel Servet

Zaragoza, , Spain

Site Status

Jan Sunnegardh's- Private Practice

Gothenburg, , Sweden

Site Status

Universitetssjukhuset i Lund

Lund, , Sweden

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

Akademiska Sjukhuset i Uppsala

Uppsala, , Sweden

Site Status

Universitetssjukhuset i Lund

Uppsala, , Sweden

Site Status

Royal Belfast Hospital for Sick Children

Belfast, , United Kingdom

Site Status

Bristol Royal Hospital for Children

Bristol, , United Kingdom

Site Status

Medway Maritime Hospital

Gillingham, , United Kingdom

Site Status

Leeds General Infirmary

Leeds, , United Kingdom

Site Status

University Hospitals of Leicester NHS Trust

Leicester, , United Kingdom

Site Status

Royal Brompton Hospital

London, , United Kingdom

Site Status

Southampton General Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Bulgaria Canada Czechia Denmark France Germany Hungary Israel Lebanon Poland Russia Spain Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MI-CP124-S2

Identifier Type: -

Identifier Source: org_study_id

NCT00240890

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVAXIN in a Pediatric Cohort
NCT04918797 COMPLETED PHASE2/PHASE3